Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Sales (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Return on Sales for 6 consecutive years, with 34.13% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales fell 2320.0% to 34.13% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.92%, a 336.0% decrease, with the full-year FY2025 number at 8.92%, down 336.0% from a year prior.
  • Return on Sales was 34.13% for Q4 2025 at Kymera Therapeutics, down from 33.51% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.4% in Q4 2023 to a low of 34.13% in Q4 2025.
  • A 5-year average of 7.7% and a median of 3.7% in 2022 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: skyrocketed 299bps in 2021, then tumbled -2320bps in 2025.
  • Kymera Therapeutics' Return on Sales stood at 0.52% in 2021, then crashed by -360bps to 2.4% in 2022, then surged by 83bps to 0.4% in 2023, then plummeted by -2603bps to 10.93% in 2024, then plummeted by -212bps to 34.13% in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Return on Sales are 34.13% (Q4 2025), 33.51% (Q3 2025), and 7.38% (Q2 2025).